The American Journal of Medicine
Volume 122, Issue 1 , Pages 4-5 , January 2009

Statin-induced Myopathy: Hypothesis About Randomized Evidence and Clinical Impressions

References 

  1. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation. 2002;106:1024–1028
  2. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators (Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins). Lancet. 2005;366:1267–1278
  3. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis; The METEOR Trial. JAMA. 2007;297:1344–1353
  4. Pharmaceutical Research and Manufacturers of America. November PhRMA Guiding Principles Direct to Consumer Advertisements about Prescription Medicines. 2005;http://www.phrma.org/files/DTCGuidingprinciples.pdfAccessed September 23, 2008
  5. Hennekens CH, Schneider WR. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Rev Cardiovasc Ther. 2008;6:95–107
  6. Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation. 1998;97:1095–1102

 Conflict of Interest: This article poses no conflicts of interest for the author. The work is original and the author meets the criteria for authorship, including acceptance of responsibility for the scientific content and writing of the article. The author's financial affiliations with all organizations, including any with a financial interest, direct or indirect, in the subject matter or materials discussed in the article that may affect the conduct or reporting of the work submitted are listed below:

 The author serves as an independent scientist in an advisory role to investigators and sponsors, including as Chair or Member on Data and Safety Monitoring Boards, for AstraZeneca, Bristol-Myers Squibb, Food and Drug Administration, Merck, National Association for Continuing Education, National Institutes of Health, Pfizer, PriMed and UpToDate. The author serves on speakers' bureaus for the International Atherosclerosis Society and AstraZeneca, concerning lipids and heart failure, as well as Pfizer, concerning lipids.

 The author receives royalties for authorship or editorship of 3 textbooks.

 The author receives royalties as co-inventor on patents concerning inflammatory markers and cardiovascular disease, which are held by Brigham and Women's Hospital.

 The author has an investment management relationship with SunTrust Bank, who has sole discretionary investment authority.

PII: S0002-9343(08)00896-6

doi: 10.1016/j.amjmed.2008.06.043

The American Journal of Medicine
Volume 122, Issue 1 , Pages 4-5 , January 2009

Article Tools